Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cogstate Ltd ( (AU:CGS) ) has provided an announcement.
Cogstate Limited announced record financial and operational performance for FY25, with significant growth driven by its Clinical Trials business. The company reported a 22% increase in group revenue to $53.1 million and a 96% rise in net profit before tax to $13.9 million. The growth was fueled by a 53% increase in new sales contracts for clinical trials, despite a decline in healthcare revenue due to changes in licensing agreements. Cogstate’s strategic partnership with Medidata and its focus on launching AI-powered products in FY26 are expected to strengthen its position in the CNS clinical research market.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.85 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Limited is a global leader in clinical trial endpoint data quality and digital cognitive assessments. The company focuses on providing scalable, technology-driven solutions to improve data quality and signal detection in Central Nervous System (CNS) clinical trials, with a strong emphasis on innovation and partnerships to enhance its market reach.
Average Trading Volume: 82,586
Technical Sentiment Signal: Buy
Current Market Cap: A$284M
For a thorough assessment of CGS stock, go to TipRanks’ Stock Analysis page.